Specific codes in ICD-10 are unique alphanumeric designations used to identify and categorize diseases, disorders, and conditions. They consist of 3-5 characters, including both letters and numbers, that provide a high level of detail and specificity.
| Language | Translation |
|---|---|
|
|
Malignant neoplasm of nasal cavity and middle ear |
|
|
Tumeur maligne des fosses nasales et de l'oreille moyenne |
| Level | Code | Title | |
|---|---|---|---|
| 1 | II | Neoplasms | |
| 2 | C00-C97 | Malignant neoplasms | |
| 3 | C30-C39 | Malignant neoplasms of respiratory and intrathoracic organs | |
| 4 | C30 | Malignant neoplasm of nasal cavity and middle ear |
| Code | Title | |
|---|---|---|
| C30.0 | Malignant neoplasm: Nasal cavity | |
| C30.1 | Malignant neoplasm: Middle ear |
| Active Ingredient |
|---|
|
Ifosfamide is an antineoplastic, a cytotoxic alkylating agent. It is a prodrug and shows no in vitro cytotoxic activity until activated by microsomal enzymes. The cytotoxic activity of ifosfamide (alkylation of the nucleophilic centres in the cells) is associated with the activated oxazaphosphorine ring hydroxylated at the C4 atom which interacts with DNA-DNA cross linking. This activity manifests itself by blocking the late S and early G2 phases of the cell cycle. |
|
Selpercatinib is an inhibitor of the rearranged during transfection (RET) receptor tyrosine kinase. Selpercatinib inhibited wild-type RET and multiple mutated RET isoforms as well as VEGFR1 and VEGFR3 with IC50 values ranging from 0.92 nM to 67.8 nM. In in vitro and in vivo tumor models, selpercatinib demonstrated anti-tumor activity in cells harboring constitutive activation of RET protein resulting from gene fusions and mutations, including CCDC6-RET, KIF5B-RET, RET V804M, and RET M918T. |